These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 28215644)

  • 21. Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy.
    Kim MJ; Kim EK; Park S; Moon HJ; Kim SI; Park BW
    Acta Radiol; 2015 Sep; 56(9):1069-77. PubMed ID: 25228161
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ixabepilone alone or with cetuximab as first-line treatment for advanced/metastatic triple-negative breast cancer.
    Trédan O; Campone M; Jassem J; Vyzula R; Coudert B; Pacilio C; Prausova J; Hardy-Bessard AC; Arance A; Mukhopadhyay P; Aloe A; Roché H
    Clin Breast Cancer; 2015 Feb; 15(1):8-15. PubMed ID: 25218708
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
    Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS
    Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of Personalized Chemoresistance Genes in Subtypes of Basal-Like Breast Cancer Based on Functional Differences Using Pathway Analysis.
    Wu T; Wang X; Li J; Song X; Wang Y; Wang Y; Zhang L; Li Z; Tian J
    PLoS One; 2015; 10(6):e0131183. PubMed ID: 26126114
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proteomics as a Guide for Personalized Adjuvant Chemotherapy in Patients with Early Breast Cancer.
    Lumachi F; Chiara GB; Foltran L; Basso SM
    Cancer Genomics Proteomics; 2015; 12(6):385-90. PubMed ID: 26543084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
    Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
    Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of dysregulated microRNAs in triple-negative breast cancer (review).
    Yang F; Zhang W; Shen Y; Guan X
    Int J Oncol; 2015 Mar; 46(3):927-32. PubMed ID: 25571912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New targets for triple-negative breast cancer.
    Herold CI; Anders CK
    Oncology (Williston Park); 2013 Sep; 27(9):846-54. PubMed ID: 24282978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
    Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
    BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intuitive repositioning of an anti-depressant drug in combination with tivozanib: precision medicine for breast cancer therapy.
    Kumar N; Raza M; Sehrawat S
    Mol Cell Biochem; 2021 Nov; 476(11):4177-4189. PubMed ID: 34324118
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRCAness is beneficial for indicating triple negative breast cancer patients resistant to taxane.
    Ishikawa T; Narui K; Tanabe M; Kida K; Oba MS; Yamada A; Ichikawa Y; Endo I
    Eur J Surg Oncol; 2016 Jul; 42(7):999-1001. PubMed ID: 27041672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic targets of triple-negative breast cancer: a review.
    Jamdade VS; Sethi N; Mundhe NA; Kumar P; Lahkar M; Sinha N
    Br J Pharmacol; 2015 Sep; 172(17):4228-37. PubMed ID: 26040571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Triple-negative breast cancer: advancements in characterization and treatment approach.
    Hurvitz S; Mead M
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579).
    Kaklamani VG; Jeruss JS; Hughes E; Siziopikou K; Timms KM; Gutin A; Abkevich V; Sangale Z; Solimeno C; Brown KL; Jones J; Hartman AR; Meservey C; Jovanovic B; Helenowski I; Khan SA; Bethke K; Hansen N; Uthe R; Giordano S; Rosen S; Hoskins K; Von Roenn J; Jain S; Parini V; Gradishar W
    Breast Cancer Res Treat; 2015 Jun; 151(3):629-38. PubMed ID: 26006067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aberrant DNA methylation status of DNA repair genes in breast cancer treated with neoadjuvant chemotherapy.
    Watanabe Y; Maeda I; Oikawa R; Wu W; Tsuchiya K; Miyoshi Y; Itoh F; Tsugawa K; Ohta T
    Genes Cells; 2013 Dec; 18(12):1120-30. PubMed ID: 24581343
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elevated TGF-β1 and -β2 expression accelerates the epithelial to mesenchymal transition in triple-negative breast cancer cells.
    Kim S; Lee J; Jeon M; Nam SJ; Lee JE
    Cytokine; 2015 Sep; 75(1):151-8. PubMed ID: 26088755
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
    Kim S; Lee J; Jeon M; Lee JE; Nam SJ
    Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. p53 status identifies triple-negative breast cancer patients who do not respond to adjuvant chemotherapy.
    Coradini D; Biganzoli E; Ardoino I; Ambrogi F; Boracchi P; Demicheli R; Daidone MG; Moliterni A
    Breast; 2015 Jun; 24(3):294-7. PubMed ID: 25698149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.